Thromb Haemost 1992; 67(01): 042-045
DOI: 10.1055/s-0038-1648376
Original Articles
Schattauer GmbH Stuttgart

Recombinant Tissue Factor as Substitute for Conventional Thromboplastin in the Prothrombin Time Test

Authors

  • Armando Tripodi

    A. Bianchi Bonomi Hemophilia and Thrombosis Center and lnstitute of lnternal Medicine, IRCCS Maggiore Hospital and University, Milano, ltaly
  • Arnaldo Arbini

    A. Bianchi Bonomi Hemophilia and Thrombosis Center and lnstitute of lnternal Medicine, IRCCS Maggiore Hospital and University, Milano, ltaly
  • Veena Chantarangkul

    A. Bianchi Bonomi Hemophilia and Thrombosis Center and lnstitute of lnternal Medicine, IRCCS Maggiore Hospital and University, Milano, ltaly
  • Pier Mannuccio Mannucci

    A. Bianchi Bonomi Hemophilia and Thrombosis Center and lnstitute of lnternal Medicine, IRCCS Maggiore Hospital and University, Milano, ltaly
Weitere Informationen

Publikationsverlauf

Received 01. Mai 1991

Accepted after revision 10. Juli 1991

Publikationsdatum:
02. Juli 2018 (online)

Preview

Summary

Relipidated recombinant tissue factor (r-TF) has been assessed in comparison with conventional rabbit brain thromboplastin (Manchester Reagent) for its suitability for measurement of prothrombin time (PT). The International Sensitivity Index (ISI) of r-TF calibrated against the International Reference Preparation BCT/253 (human plain) was found to be 0.96 and 1.12 with instrumental and manual techniques. Our study of plasmas from patients with congenital deficiencies of clotting factors covering a wide range of severity demonstrates that r-TF is able to detect even minor deficiencies of factors involved in the extrinsic and common coagulation pathways. Patients with liver diseases were correctly diagnosed with a prevalence of abnormal results comparable for both reagents. Between-assay reproducibility expressed as coefficient of variation was 2.3 % and 3.9 % at normal and abnormal PT levels.

In conclusion, our evaluation shows that relipidated r-TF possesses the necessary requisites of sensitivity, diagnostic accuracy and reproducibility which make it a suitable candidate for PT determination both for monitoring oral anticoagulant therapy and diagnosing congenital and acquired clotting factor deficiencies. Moreover, being a highly defined reagent it may constitute a step forward in the standardization of PT testing.